We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for Teprotumumab (Amgen Australia Pty Ltd)
Active ingredients
Teprotumumab
Sponsor
Date of review outcome
Lapse date
Type
Priority Review
Indication
Treatment of thyroid eye disease
Therapeutic area
Endocrinology